Tech Company Financing Transactions

Attune Pharmaceuticals Funding Round

Venrock, Boxer Capital and LifeSci Venture Partners participated in a $23 million Series B capital raise for Attune Pharmaceuticals. The round was recorded on 1/24/2019.

Transaction Overview

Announced On
1/24/2019
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Proceeds Purpose
Proceeds of the Series B round will be used to advance Attune's pipeline, which includes the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
250 West 55th St. 34th Floor
New York, NY 10019
USA
Email Address
Overview
Attune Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel once-daily small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals is currently advancing two programs, one in Hereditary Angioedema (HAE) and a second in complement-mediated diseases.
Profile
Attune Pharmaceuticals LinkedIn Company Profile
Social Media
Attune Pharmaceuticals Company Twitter Account
Company News
Attune Pharmaceuticals News
Facebook
Attune Pharmaceuticals on Facebook
YouTube
Attune Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Andrew McDonald
  Andrew McDonald LinkedIn Profile  Andrew McDonald Twitter Account  Andrew McDonald News  Andrew McDonald on Facebook
Chief Marketing Officer
Ira Kalfus
  Ira Kalfus LinkedIn Profile  Ira Kalfus Twitter Account  Ira Kalfus News  Ira Kalfus on Facebook
Chief Operating Officer
Jason Bablak
  Jason Bablak LinkedIn Profile  Jason Bablak Twitter Account  Jason Bablak News  Jason Bablak on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/24/2019: Confluent venture capital transaction
Next: 1/24/2019: Urgent.ly venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary